Christopher Thomas Appleton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Thomas Appleton has a total of 419 co-authors. Here are the top co-authors by number of shared publications:
- Trevor B. Birmingham
School of Physical Therapy, Western University, London, ON, Canada
12 shared publications - Holly T. Philpott
University of Western Ontario and London Health Sciences Centre‐University Hospital London Ontario Canada
11 shared publications F. Beier
7 shared publications- James Robert Giffin
University of Western Ontario, London, Ontario, Canada
6 shared publications - L. Stefan Lohmander
Department of Clinical Sciences Lund, Orthopedics, Lund University, Lund, Sweden
6 shared publications - Brent Andrew Lanting
Division of Orthopaedic Surgery, Department of Surgery, Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, Ontario, Canada
5 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4)
Acute TGFα drives OA-associated transcriptional and metabolic remodelling in primary chondrocytes
- 2 September 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4)
Open AccessAcute TGFα drives OA-associated transcriptional and metabolic remodelling in primary chondrocytes
- Top Cited PapersOpen Access
- 2 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum
Knee osteoarthritis affects 40% of people during their lifetime, significantly impacting societies worldwide. Its molecular pathogenesis remains poorly understood and variable clinical phenotypes suggest it may be more than one disease. We established S ynovial fluid T o detect E ndoty p es by U nbiased P roteomics in OA (STEpUP OA) to search for molecular endotypes in knee OA synovial fluid, and to reveal key pathobiological pathways across 1361 individuals with knee OA. Using unsupervised clustering, a single cluster representing a biological continuum is observed, primarily driven by “Epithelial Mesenchymal Transition”. Distinct molecular endotypes are not detected. “Angiogenesis”, “Complement” and “Coagulation” are enriched for after stratification by clinical phenotype (obesity status, biological sex). Complement and coagulation are associated with the inflammatory marker, C-reactive protein. Associations with patient-reported knee pain are weaker. These findings support knee OA as a biological continuum, identify common and phenotype-enriched targetable pathways, and a rationale for stratification in clinical trial design.
- 2 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessLarge-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum
Knee osteoarthritis affects 40% of people during their lifetime, significantly impacting societies worldwide. Its molecular pathogenesis remains poorly understood and variable clinical phenotypes suggest it may be more than one disease. We established S ynovial fluid T o detect E ndoty p es by U nbiased P roteomics in OA (STEpUP OA) to search for molecular endotypes in knee OA synovial fluid, and to reveal key pathobiological pathways across 1361 individuals with knee OA. Using unsupervised clustering, a single cluster representing a biological continuum is observed, primarily driven by “Epithelial Mesenchymal Transition”. Distinct molecular endotypes are not detected. “Angiogenesis”, “Complement” and “Coagulation” are enriched for after stratification by clinical phenotype (obesity status, biological sex). Complement and coagulation are associated with the inflammatory marker, C-reactive protein. Associations with patient-reported knee pain are weaker. These findings support knee OA as a biological continuum, identify common and phenotype-enriched targetable pathways, and a rationale for stratification in clinical trial design.
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2)
Metabolic syndrome and knee osteoarthritis: associations with disease stage and pain
Objectives: Metabolic Syndrome (MetS) is associated with OA progression and pain. However, its relationship with outcomes in early-stage disease remains unclear. We assessed associations of MetS with radiographic stage and knee pain in individuals with symptomatic knee OA. Methods: We analysed cross-sectional baseline data from 251 participants in the Western Ontario Registry for Early Osteoarthritis (WOREO) Knee Study. Associations between MetS and radiographic stage were assessed using modified Poisson regression. Associations with knee pain, measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS) pain scale, were evaluated using multiple linear regression accounting for within-participant correlation. Analyses were stratified by OA stage and adjusted for body mass index (BMI). Results: MetS was associated with a higher prevalence of late-stage knee OA [adjusted prevalence ratio 1.45 (95% CI 1.16, 1.81)]. After BMI adjustment, hypertension and haemoglobin A1c remained associated with late-stage disease. Participants with MetS reported worse knee pain, with lower KOOS pain scores [β = −14.70 (95% CI −20.92, −8.47)], particularly in early-stage disease [β = −14.15 (95% CI −20.37, −7.93)]. Dyslipidaemia (elevated triglycerides and reduced high-density lipoprotein cholesterol were also associated with worse pain in early-stage disease. Conclusion: MetS and its components are associated with greater radiographic severity and clinically meaningful worsening of pain, especially in early-stage knee OA, independent of BMI. These findings suggest that early identification and management of metabolic disease may represent a modifiable target to improve OA outcomes.
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2)
Open AccessMetabolic syndrome and knee osteoarthritis: associations with disease stage and pain
Objectives: Metabolic Syndrome (MetS) is associated with OA progression and pain. However, its relationship with outcomes in early-stage disease remains unclear. We assessed associations of MetS with radiographic stage and knee pain in individuals with symptomatic knee OA. Methods: We analysed cross-sectional baseline data from 251 participants in the Western Ontario Registry for Early Osteoarthritis (WOREO) Knee Study. Associations between MetS and radiographic stage were assessed using modified Poisson regression. Associations with knee pain, measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS) pain scale, were evaluated using multiple linear regression accounting for within-participant correlation. Analyses were stratified by OA stage and adjusted for body mass index (BMI). Results: MetS was associated with a higher prevalence of late-stage knee OA [adjusted prevalence ratio 1.45 (95% CI 1.16, 1.81)]. After BMI adjustment, hypertension and haemoglobin A1c remained associated with late-stage disease. Participants with MetS reported worse knee pain, with lower KOOS pain scores [β = −14.70 (95% CI −20.92, −8.47)], particularly in early-stage disease [β = −14.15 (95% CI −20.37, −7.93)]. Dyslipidaemia (elevated triglycerides and reduced high-density lipoprotein cholesterol were also associated with worse pain in early-stage disease. Conclusion: MetS and its components are associated with greater radiographic severity and clinically meaningful worsening of pain, especially in early-stage knee OA, independent of BMI. These findings suggest that early identification and management of metabolic disease may represent a modifiable target to improve OA outcomes.
- 4 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152913
Exploring the association between adiposity, pain intensity, and effusion-synovitis in people with knee osteoarthritis: A cross-sectional study
- 4 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152913
Exploring the association between adiposity, pain intensity, and effusion-synovitis in people with knee osteoarthritis: A cross-sectional study
- 5 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (1) , 2-4
Tribute to Dr. Frank Beier (1965–2025)
- 5 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (1) , 2-4
Tribute to Dr. Frank Beier (1965–2025)
- Open Access
- 12 October 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (3) , 432-447
Fibroblast and myeloid cells with high mitochondrial RNA content represent biologically significant populations within the OA synovium
- 12 October 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (3) , 432-447
Open AccessFibroblast and myeloid cells with high mitochondrial RNA content represent biologically significant populations within the OA synovium
- Open Access
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (4) , 376-385
Evaluating Implementation Context to Prepare for Scaling Up the Integration of Interdisciplinary Healthcare Providers in Rheumatology Practices: A Rheumatology Workforce Survey
Objective: Interdisciplinary healthcare providers (IHPs) can support effective delivery of optimal rheumatology care. To inform widespread implementation efforts, we assessed rheumatology workforce characteristics and determinants of integrating of IHPs within rheumatology practices in Ontario, Canada. Methods: A convergent mixed methods design included an environmental scan to identify clinically active rheumatologists and a workforce survey guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Quantitative data were analyzed descriptively and stratified by subgroups. Qualitative responses were analyzed using conventional content analysis. Integration of findings enabled a comprehensive understanding of implementation determinants. Results: Of the 293 Ontario rheumatologists identified by the environmental scan (as of 2025), 26 were nearing retirement, leaving potentially 267 eligible for the survey. One hundred ninety-seven rheumatologists participated in the survey, yielding a response rate of 74% and coverage of > 90% of practice sites. Pediatric rheumatologists and those in hospital-based settings had more structural and collaborative supports than community-based rheumatologists. Overall, 177 (91%) indicated they were interested in adding IHPs, with 126 (65%) preferring an extended role/scope provider. Although inadequate funding was the key deterrent to adoption, motivational readiness was high: 92% perceived an IHP team-based model as an improvement, 86% saw it as a good fit, and 83% considered it a priority to better meet patient needs. Many noted a lack of supportive climate, including that of resources and processes, to enable this practice change. Conclusion: Rheumatologists report high motivation for practice change to integrate IHPs. System- and practice-level implementation strategies are needed to support workforce transformation.
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (4) , 376-385
Open AccessEvaluating Implementation Context to Prepare for Scaling Up the Integration of Interdisciplinary Healthcare Providers in Rheumatology Practices: A Rheumatology Workforce Survey
Objective: Interdisciplinary healthcare providers (IHPs) can support effective delivery of optimal rheumatology care. To inform widespread implementation efforts, we assessed rheumatology workforce characteristics and determinants of integrating of IHPs within rheumatology practices in Ontario, Canada. Methods: A convergent mixed methods design included an environmental scan to identify clinically active rheumatologists and a workforce survey guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Quantitative data were analyzed descriptively and stratified by subgroups. Qualitative responses were analyzed using conventional content analysis. Integration of findings enabled a comprehensive understanding of implementation determinants. Results: Of the 293 Ontario rheumatologists identified by the environmental scan (as of 2025), 26 were nearing retirement, leaving potentially 267 eligible for the survey. One hundred ninety-seven rheumatologists participated in the survey, yielding a response rate of 74% and coverage of > 90% of practice sites. Pediatric rheumatologists and those in hospital-based settings had more structural and collaborative supports than community-based rheumatologists. Overall, 177 (91%) indicated they were interested in adding IHPs, with 126 (65%) preferring an extended role/scope provider. Although inadequate funding was the key deterrent to adoption, motivational readiness was high: 92% perceived an IHP team-based model as an improvement, 86% saw it as a good fit, and 83% considered it a priority to better meet patient needs. Many noted a lack of supportive climate, including that of resources and processes, to enable this practice change. Conclusion: Rheumatologists report high motivation for practice change to integrate IHPs. System- and practice-level implementation strategies are needed to support workforce transformation.
- Open Access
- 1 October 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-10
Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review
Immune checkpoint inhibitors (ICIs) have been associated with immune-related adverse events (irAEs), including ICI associated vasculitis (ICI-vasculitis) and ICI associated PMR (ICI-polymyalgia rheumatica (PMR)-like syndromes). We sought to describe the characteristics of ICI-vasculitis and ICI-PMR in individuals treated with ICIs through a systematic review and local case series. We searched MEDLINE and Embase from inception to July 2023 for cases of ICI-vasculitis and ICI-PMR in ICI-treated individuals. Our series included cases obtained from clinicians at the Universities of Toronto, McMaster, and Western in Ontario, Canada. One hundred and forty-four patients were identified: 130 from the systematic review in 76 articles and 14 from our case series. This included 73 patients with ICI-vasculitis (14 large vessel, 7 ANCA-associated, 52 other) and 71 with ICI-PMR. Ninety-five per cent of patients were treated with glucocorticoids and 17% received disease-modifying antirheumatic drugs (DMARDs). Among 4 individuals with vasculitis who continued the ICI, two remitted. Of five who paused and restarted ICIs, one experienced a recurrence. Among four individuals with vasculitis who continued ICIs, two remitted. All 11 ICI-PMR cases that continued ICIs remitted; among 3 patients who paused and restarted two did not relapse and one had a relapse that improved with an increase in their dose of prednisone. ICI-vasculitis and ICI-PMR are underrecognized complications of ICIs. Glucocorticoids are effective for ICI-vasculitis and ICI-PMR. It is unclear if ICIs can be safely continued or restarted after remission of ICI-vasculitis or ICI-PMR. Limited data suggests ICIs may be resumed in individuals with non-severe ICI-vasculitis or ICI-PMR.
- 1 October 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-10
Open AccessImmune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review
Immune checkpoint inhibitors (ICIs) have been associated with immune-related adverse events (irAEs), including ICI associated vasculitis (ICI-vasculitis) and ICI associated PMR (ICI-polymyalgia rheumatica (PMR)-like syndromes). We sought to describe the characteristics of ICI-vasculitis and ICI-PMR in individuals treated with ICIs through a systematic review and local case series. We searched MEDLINE and Embase from inception to July 2023 for cases of ICI-vasculitis and ICI-PMR in ICI-treated individuals. Our series included cases obtained from clinicians at the Universities of Toronto, McMaster, and Western in Ontario, Canada. One hundred and forty-four patients were identified: 130 from the systematic review in 76 articles and 14 from our case series. This included 73 patients with ICI-vasculitis (14 large vessel, 7 ANCA-associated, 52 other) and 71 with ICI-PMR. Ninety-five per cent of patients were treated with glucocorticoids and 17% received disease-modifying antirheumatic drugs (DMARDs). Among 4 individuals with vasculitis who continued the ICI, two remitted. Of five who paused and restarted ICIs, one experienced a recurrence. Among four individuals with vasculitis who continued ICIs, two remitted. All 11 ICI-PMR cases that continued ICIs remitted; among 3 patients who paused and restarted two did not relapse and one had a relapse that improved with an increase in their dose of prednisone. ICI-vasculitis and ICI-PMR are underrecognized complications of ICIs. Glucocorticoids are effective for ICI-vasculitis and ICI-PMR. It is unclear if ICIs can be safely continued or restarted after remission of ICI-vasculitis or ICI-PMR. Limited data suggests ICIs may be resumed in individuals with non-severe ICI-vasculitis or ICI-PMR.
- 17 June 2025
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 66 (5) , 331-338
Synovial joint organ homeostasis: mechanisms and biological considerations
Synovial joints are complex multi-tissue organs that permit movement. A well-functioning synovial joint relies on complex interconnected homeostatic mechanisms to maintain joint organ function in response to biomechanical and metabolic demands. These homeostatic mechanisms include, but are not limited to, appropriate mechanobiological responses to load, nutrient delivery from its vasculature, lubrication, proprioception and pain, immunosurveillance, and maintenance of the extracellular matrix (ECM) composition. In osteoarthritis (OA), joint homeostasis is chronically deranged leading to failure of the synovial joint organ and impairment or loss of function. Maintaining synovial joint organ homeostasis is therefore critical to joint function and relies on complex interconnected physiological process at the joint level. As OA prevalence continues to rise, deepening our understanding of the integrated systems that sustain joint homeostasis may identify fruitful avenues for therapeutic intervention. However, key knowledge gaps will need to be addressed including, characterizing vessel function in joint diseases, understanding the role of novel proteases in ECM catabolism, and determining the role of non-macrophage synovial immune cells in joint immunosurveillance. We believe that future research will find greater success if these homeostatic mechanisms are viewed as a single integrated system that considers the crosstalk between mechanical, vascular, immune, and biochemical factors. Therefore, in this review, we explore the interconnected mechanisms that support joint homeostasis and how dysregulation can lead to failure of the synovial joint organ.
- 17 June 2025
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 66 (5) , 331-338
Synovial joint organ homeostasis: mechanisms and biological considerations
Synovial joints are complex multi-tissue organs that permit movement. A well-functioning synovial joint relies on complex interconnected homeostatic mechanisms to maintain joint organ function in response to biomechanical and metabolic demands. These homeostatic mechanisms include, but are not limited to, appropriate mechanobiological responses to load, nutrient delivery from its vasculature, lubrication, proprioception and pain, immunosurveillance, and maintenance of the extracellular matrix (ECM) composition. In osteoarthritis (OA), joint homeostasis is chronically deranged leading to failure of the synovial joint organ and impairment or loss of function. Maintaining synovial joint organ homeostasis is therefore critical to joint function and relies on complex interconnected physiological process at the joint level. As OA prevalence continues to rise, deepening our understanding of the integrated systems that sustain joint homeostasis may identify fruitful avenues for therapeutic intervention. However, key knowledge gaps will need to be addressed including, characterizing vessel function in joint diseases, understanding the role of novel proteases in ECM catabolism, and determining the role of non-macrophage synovial immune cells in joint immunosurveillance. We believe that future research will find greater success if these homeostatic mechanisms are viewed as a single integrated system that considers the crosstalk between mechanical, vascular, immune, and biochemical factors. Therefore, in this review, we explore the interconnected mechanisms that support joint homeostasis and how dysregulation can lead to failure of the synovial joint organ.
- Open Access
- 26 May 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (9) , 1147-1152
Elucidating the initial symptoms and experiences of knee osteoarthritis: An international patient survey
- 26 May 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (9) , 1147-1152
Open AccessElucidating the initial symptoms and experiences of knee osteoarthritis: An international patient survey